Form 4: BridgeBio Oncology: Former Director's Share Conversion
Insider Transaction Report
A former director of Helix Acquisition Corp. II converted 30,000 Class B ordinary shares into common stock of BridgeBio Oncology Therapeutics, Inc. following a business combination and domestication.
Summary
- John P. Schmid, a former director of Helix Acquisition Corp. II, reported changes in beneficial ownership.
- The filing pertains to BridgeBio Oncology Therapeutics, Inc. (BBOT), which was formerly known as Helix Acquisition Corp. II.
- On August 11, 2025, 30,000 Class B ordinary shares of Helix were converted into 30,000 Class A ordinary shares, which subsequently converted into 30,000 shares of the Issuer's common stock.
- This conversion was a result of a business combination between Helix Acquisition Corp. II and TheRas, Inc., and Helix's domestication as a Delaware corporation.
- John P. Schmid resigned from his role as a director of Helix effective August 11, 2025, immediately prior to the domestication.
Sentiment
Score: 5
Explanation: The filing is neutral, reporting a factual, procedural change in beneficial ownership and a director's resignation following a corporate restructuring event.
Future Outlook
No forward-looking statements or guidance are provided in this filing.
Management Comments
- The Reporting person was a director of Helix prior to the Domestication and resigned from such role effective as of August 11, 2025, immediately prior to the Domestication.
Industry Context
This filing reflects a common procedural step following a Special Purpose Acquisition Company (SPAC) business combination and subsequent domestication, where the SPAC's original share classes are converted into the common stock of the newly formed operating company. Such transactions are frequent in the biotechnology and pharmaceutical sectors as companies transition to public listing.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | John P. Schmid (of Helix Acquisition Corp. II) | N/A | 08/11/2025 | Resignation immediately prior to the domestication of Helix Acquisition Corp. II into BridgeBio Oncology Therapeutics, Inc. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Corporate Structure Change | Helix Acquisition Corp. II migrated and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law and the Cayman Islands Companies Act (As Revised). | 08/11/2025 | This domestication changes the company's legal domicile and governing corporate law, potentially impacting shareholder rights, corporate compliance, and regulatory oversight. |
Stakeholder Impact
- Shareholders of Helix Acquisition Corp. II had their Class B ordinary shares converted into common stock of the newly formed BridgeBio Oncology Therapeutics, Inc. as part of the business combination and domestication.
Key Dates
| Date | Description |
|---|---|
| 08/11/2025 | Transaction date for share conversion and effective date of director resignation. |
Keywords
BridgeBio Oncology Therapeutics, BBOT, Helix Acquisition Corp. II, TheRas Inc., Form 4, beneficial ownership, share conversion, domestication, director resignation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.